Switch theme
Sign up to access all valuation multiples
Celltrion Pharm Inc is active in the Korean healthcare sector. Its core business includes the manufacture and sale of pharmaceuticals such as heptatonic, analgesics, antipyretics, anti-inflammatory drugs, antihistamines, respiratory apparatus drugs and antibiotics.
1976
n/a
LTM Revenue n/a
LTM EBITDA n/a
$1.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Celltrion Pharm has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Celltrion Pharm achieved revenue of $326M and an EBITDA of $39.1M.
Celltrion Pharm expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Celltrion Pharm valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $265M | $326M | XXX | XXX | XXX |
| Gross Profit | $76.8M | $81.6M | XXX | XXX | XXX |
| Gross Margin | 29% | 25% | XXX | XXX | XXX |
| EBITDA | $36.9M | $39.1M | XXX | XXX | XXX |
| EBITDA Margin | 14% | 12% | XXX | XXX | XXX |
| Net Profit | $17.7M | $14.5M | XXX | XXX | XXX |
| Net Margin | 7% | 4% | XXX | XXX | XXX |
| Net Debt | $87.8M | $94.3M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Celltrion Pharm's stock price is KRW 48100 (or $33).
Celltrion Pharm has current market cap of KRW 2.09T (or $1.4B), and EV of KRW 2.19T (or $1.5B).
See Celltrion Pharm trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.5B | $1.4B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Celltrion Pharm has market cap of $1.4B and EV of $1.5B.
Celltrion Pharm's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Celltrion Pharm's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Celltrion Pharm and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.5B | XXX | XXX | XXX |
| EV/Revenue | 4.6x | XXX | XXX | XXX |
| EV/EBITDA | 38.2x | XXX | XXX | XXX |
| P/E | 95.2x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 43.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpCelltrion Pharm's NTM/LTM revenue growth is n/a
Celltrion Pharm's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Celltrion Pharm's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Celltrion Pharm's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Celltrion Pharm and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 23% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 6% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 5% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 18% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Celltrion Pharm acquired XXX companies to date.
Last acquisition by Celltrion Pharm was XXXXXXXX, XXXXX XXXXX XXXXXX . Celltrion Pharm acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Celltrion Pharm founded? | Celltrion Pharm was founded in 1976. |
| Where is Celltrion Pharm headquartered? | Celltrion Pharm is headquartered in South Korea. |
| Who is the CEO of Celltrion Pharm? | Celltrion Pharm's CEO is Mr. Jung-su Seo. |
| Is Celltrion Pharm publicy listed? | Yes, Celltrion Pharm is a public company listed on KRX. |
| What is the stock symbol of Celltrion Pharm? | Celltrion Pharm trades under 068760 ticker. |
| When did Celltrion Pharm go public? | Celltrion Pharm went public in 2006. |
| Who are competitors of Celltrion Pharm? | Similar companies to Celltrion Pharm include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Celltrion Pharm? | Celltrion Pharm's current market cap is $1.4B |
| What is the current revenue growth of Celltrion Pharm? | Celltrion Pharm revenue growth between 2023 and 2024 was 23%. |
| Is Celltrion Pharm profitable? | Yes, Celltrion Pharm is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
